New Zealand Greenlights MDMA-Assisted Therapy for Severe PTSD

New Zealand has taken a significant step in mental health treatment by approving the use of pharmaceutical-grade MDMA for patients suffering from severe post-traumatic stress disorder (PTSD). The country's drug regulator, Medsafe, granted two psychiatrists the authority to prescribe the substance on Friday.

This decision makes New Zealand only the second nation globally to sanction the use of the substance, commonly known as the party drug ecstasy, for therapeutic purposes. Australia had previously approved the treatment in 2023.

Deputy Prime Minister David Seymour, who had earlier supported the use of magic mushrooms for severe depression, highlighted the potential benefits of the treatment. "PTSD ruins lives and is difficult to treat," he stated, adding that MDMA can be highly effective when used within psychedelic-assisted therapy. He affirmed the country's commitment to expanding access to innovative medical treatments.

PTSD is a debilitating mental health condition that can develop following exposure to traumatic events, such as combat, sexual assault, or the threat of death. The approval comes as clinical trials for MDMA's medicinal use continue in the United States, where the Food and Drug Administration rejected its legalisation in 2024 due to insufficient evidence of its safety and efficacy.

In New Zealand, the treatment will be strictly regulated. The Ministry of Health confirmed that MDMA-assisted therapy will be combined with psychotherapy and administered in a controlled clinical environment under the supervision of an authorised psychiatrist. Patients will not be permitted to take the drug home, and eligibility is restricted to individuals aged 18 and older.

The move is seen as a progressive step in addressing the limitations of current PTSD treatments, which have often shown uneven results.